Rafal Wierzbicki - Concepedia

Concepedia

Author

Rafal Wierzbicki

Regional Municipality of Durham

Also Known As

R Wierzbicki, R. Wierzbicki, Rafal F. Wierzbicki, Rafal Wierzbicki, Wierzbicki Rafal

41

Publications

2.4K

Citations

15

H-Index

38

Concepts

All Affiliations

Regional Municipality of Durham Princess Margaret Cancer Centre Lakeridge Health Dana-Farber Cancer Institute University of Ottawa

RW

About

Rafal Wierzbicki is an author at Regional Municipality of Durham specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	912
2	Health Sciences	8	8	655
3	Engineering	1	1	38
4	Gastroenterology	1	1	14
5	Hepatology	1	1	14

Rafal Wierzbicki

×

21

Publications

2.4K

Citations

15

H-Index

	Year	Citations
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study Charles S. Fuchs, John L. Marshall, Edith P. Mitchell, Journal of Clinical Oncology	2007	854
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Robert L. Souhami, Alan Craft, Jan W. van der Eijken, The Lancet Surgical OncologyMedicineCancer ManagementMetronomic TherapyEuropean Osteosarcoma Intergroup	1997	381
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Journal of Clinical Oncology	2012	232
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczęsna, Journal of Clinical Oncology	2012	211
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial Peter Ellis, Frances A. Shepherd, Michael Millward, The Lancet Oncology Pretreated PatientsOncologyNcic Ctg Br.26Clinical TrialsImmune Checkpoint Inhibitor	2014	125
Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non–Small-Cell Lung Cancer and Poor Performance Status Glenwood Goss, David Ferry, Rafal Wierzbicki, Journal of Clinical Oncology	2009	116
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Luis Paz‐Ares, Beatrix Bálint, Richard H. De Boer, Journal of Thoracic Oncology Randomized Phase 2MedicinePharmacologyPathologyImmune Checkpoint Inhibitor	2013	71
A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer Peter Ellis, Natasha B. Leighl, Vera Hirsh, Clinical Lung Cancer Second-line TreatmentMedicinePemetrexed MonotherapyMetronomic TherapyPharmacology	2015	56
A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) Charles S. Fuchs, J. Marshall, Edith P. Mitchell, Journal of Clinical Oncology Gastrointestinal OncologyMedicineCelecoxib Vs PlaceboPharmacologyClinical Trials	2006	54
A Phase II Study of Recombinant Tumor Necrosis Factor in Renal Cell Carcinoma Jamey Skillings, Rafal Wierzbicki, Elizabeth A. Eisenhauer, Journal of Immunotherapy	1992	41

Page 1